Preconception Weight Loss With Liraglutide Protects Pregnant Mouse Kidneys

Losing weight before pregnancy with either diet change or liraglutide improved maternal kidney outcomes in obese mice during late pregnancy.

Rodrigo, Natassia et al.·Scientific reports·2024·Preliminary Evidenceanimal study
RPEP-09161Animal studyPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal study
Evidence
Preliminary Evidence
Sample
C57BL/6 female mice with diet-induced obesity
Participants
C57BL/6 female mice with diet-induced obesity

What This Study Found

Preconception weight loss through either diet modification or liraglutide treatment improved maternal kidney outcomes in late gestation in a mouse model of obesity.

Key Numbers

C57BL/6 female mice were fed high-fat diet for 8 weeks. Weight loss was induced either by switching to chow diet or by liraglutide (a GLP-1 agonist).

How They Did This

Animal study using C57BL/6 female mice fed high-fat diet for 8 weeks, then randomized to continued HFD, diet switch, or liraglutide before mating.

Why This Research Matters

Obesity-related kidney problems during pregnancy are a growing concern. Showing that preconception weight loss protects the kidneys gives doctors a clear intervention window.

The Bigger Picture

Obesity-related kidney problems during pregnancy are a growing concern. Identifying a clear preconception intervention window where weight loss protects the kidneys could improve maternal and fetal outcomes.

What This Study Doesn't Tell Us

This is a mouse study, and kidney responses during pregnancy may differ in humans. Liraglutide is not currently approved for preconception use.

Questions This Raises

  • ?Would these findings translate to human preconception care?
  • ?Is liraglutide safe in the preconception period in women planning pregnancy?

Trust & Context

Key Stat:
Both interventions protective Whether weight was lost through diet change or liraglutide, kidney outcomes improved equally during late pregnancy
Evidence Grade:
Rated preliminary: animal study demonstrating proof of concept. Liraglutide is not currently approved or recommended for preconception use in humans.
Study Age:
Published in 2024. Adds to growing evidence about the importance of preconception metabolic health.
Original Title:
Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.
Published In:
Scientific reports, 14(1), 17363 (2024)
Database ID:
RPEP-09161

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Should women lose weight before getting pregnant?

This mouse study supports the concept that preconception weight loss protects maternal kidney health. Weight loss is generally recommended before pregnancy for obese women.

Can you take liraglutide before getting pregnant?

GLP-1 drugs should be stopped before conception. This study shows preconception use in mice protected kidneys, but human preconception safety data is not available.

Read More on RethinkPeptides

Cite This Study

RPEP-09161·https://rethinkpeptides.com/research/RPEP-09161

APA

Rodrigo, Natassia; Chen, Hui; Pollock, Carol A; Glastras, Sarah J. (2024). Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.. Scientific reports, 14(1), 17363. https://doi.org/10.1038/s41598-024-68234-9

MLA

Rodrigo, Natassia, et al. "Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.." Scientific reports, 2024. https://doi.org/10.1038/s41598-024-68234-9

RethinkPeptides

RethinkPeptides Research Database. "Kidney outcomes are altered by preconception weight modulati..." RPEP-09161. Retrieved from https://rethinkpeptides.com/research/rodrigo-2024-kidney-outcomes-are-altered

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.